Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)
EICHORPublic-registry site landscape for NCT07743541, “Study of TUB-040 in Patients With Recurrent or Progressive Uterine Cancer After Chemotherapy and Immune Therapy”, a Uterine Endometrial Cancer study sponsored by Tubulis GmbH. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07743541 (registry record) |
| Study title | Study of TUB-040 in Patients With Recurrent or Progressive Uterine Cancer After Chemotherapy and Immune Therapy |
| Official title | A Multicenter Phase 1/2 Study to Investigate Safety, Tolerability, Pharmacokinetics, and Efficacy of the NaPi2B Antibody-Drug Conjugate TUB-040 in Patients With Recurrent or Progressive Uterine Endometrial Cancer After Platinum-Based Chemotherapy and Immune Checkpoint Inhibitor Therapy |
| Sponsor | Tubulis GmbH |
| Condition(s) | Uterine Endometrial Cancer |
| Phase | PHASE1 / PHASE2 |
| Listed sites | 4 |
| Site countries | United States |
At START Los Angeles — one of the facilities listed on this trial — 2 other studies are actively recruiting Uterine Endometrial Cancer patients at the same facility (public registry, as of August 2026). Facility-level recruiting density is one of the strongest public correlates of enrollment pace in an indication.
Patient-friendly overview of this study: eichor.com/study/NCT07743541.
Eichor generates a preliminary site-risk snapshot for NCT07743541 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →